The antibody–drug conjugate ifinatamab deruxtecan (I-DXd) showed clinically meaningful responses in pretreated patients with extensive-stage small cell lung cancer (ES-SCLC), according to an interim analysis of the Phase 2 IDeate-Lung01 study.
Emergent to shut facilities and lay off workers as part of new CEO’s roadmap
Newly appointed CEO Joe Papa outlined his vision for Emergent BioSolutions, which includes winding down two facilities and laying off 300 employees to save $80